These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Mast Cell Proteases Activate Astrocytes and Glia-Neurons and Release Interleukin-33 by Activating p38 and ERK1/2 MAPKs and NF-κB. Kempuraj D; Thangavel R; Selvakumar GP; Ahmed ME; Zaheer S; Raikwar SP; Zahoor H; Saeed D; Dubova I; Giler G; Herr S; Iyer SS; Zaheer A Mol Neurobiol; 2019 Mar; 56(3):1681-1693. PubMed ID: 29916143 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review. Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973 [TBL] [Abstract][Full Text] [Related]
25. Absence of glia maturation factor protects dopaminergic neurons and improves motor behavior in mouse model of parkinsonism. Khan MM; Zaheer S; Thangavel R; Patel M; Kempuraj D; Zaheer A Neurochem Res; 2015 May; 40(5):980-90. PubMed ID: 25754447 [TBL] [Abstract][Full Text] [Related]
26. Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases. Kempuraj D; Khan MM; Thangavel R; Xiong Z; Yang E; Zaheer A J Neuroimmune Pharmacol; 2013 Jun; 8(3):643-50. PubMed ID: 23397250 [TBL] [Abstract][Full Text] [Related]
27. Cross-Talk between Glia, Neurons and Mast Cells in Neuroinflammation Associated with Parkinson's Disease. Kempuraj D; Selvakumar GP; Zaheer S; Thangavel R; Ahmed ME; Raikwar S; Govindarajan R; Iyer S; Zaheer A J Neuroimmune Pharmacol; 2018 Mar; 13(1):100-112. PubMed ID: 28952015 [TBL] [Abstract][Full Text] [Related]
28. First description of enhanced expression of transforming growth factor-alpha (TGF-α) and glia maturation factor-beta (GMF-β) correlate with severity of neuropathology in border disease virus-infected small ruminants. Dincel GC; Kul O Microb Pathog; 2019 Mar; 128():301-310. PubMed ID: 30654008 [TBL] [Abstract][Full Text] [Related]
29. Neuroinflammation and protein pathology in Parkinson's disease dementia. Kouli A; Camacho M; Allinson K; Williams-Gray CH Acta Neuropathol Commun; 2020 Dec; 8(1):211. PubMed ID: 33272323 [TBL] [Abstract][Full Text] [Related]
30. Dopaminergic Toxin 1-Methyl-4-Phenylpyridinium, Proteins α-Synuclein and Glia Maturation Factor Activate Mast Cells and Release Inflammatory Mediators. Kempuraj D; Thangavel R; Yang E; Pattani S; Zaheer S; Santillan DA; Santillan MK; Zaheer A PLoS One; 2015; 10(8):e0135776. PubMed ID: 26275153 [TBL] [Abstract][Full Text] [Related]
31. NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease. Sirabella R; Sisalli MJ; Costa G; Omura K; Ianniello G; Pinna A; Morelli M; Di Renzo GM; Annunziato L; Scorziello A Cell Death Dis; 2018 Jun; 9(7):725. PubMed ID: 29941946 [TBL] [Abstract][Full Text] [Related]
32. Glia maturation factor regulation of STAT expression: a novel mechanism in experimental autoimmune encephalomyelitis. Zaheer S; Wu Y; Bassett J; Yang B; Zaheer A Neurochem Res; 2007 Dec; 32(12):2123-31. PubMed ID: 17551829 [TBL] [Abstract][Full Text] [Related]
33. L-alpha-aminoadipic acid restricts dopaminergic neurodegeneration and motor deficits in an inflammatory model of Parkinson's disease in male rats. O'Neill E; Chiara Goisis R; Haverty R; Harkin A J Neurosci Res; 2019 Jul; 97(7):804-816. PubMed ID: 30924171 [TBL] [Abstract][Full Text] [Related]
34. Dementia, gliosis and expression of the small heat shock proteins hsp27 and alpha B-crystallin in Parkinson's disease. Renkawek K; Stege GJ; Bosman GJ Neuroreport; 1999 Aug; 10(11):2273-6. PubMed ID: 10439447 [TBL] [Abstract][Full Text] [Related]
35. Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. de la Monte SM; Wells SE; Hedley-Whyte T; Growdon JH Ann Neurol; 1989 Sep; 26(3):309-20. PubMed ID: 2802531 [TBL] [Abstract][Full Text] [Related]
36. Glia maturation factor modulates beta-amyloid-induced glial activation, inflammatory cytokine/chemokine production and neuronal damage. Zaheer A; Zaheer S; Thangavel R; Wu Y; Sahu SK; Yang B Brain Res; 2008 May; 1208():192-203. PubMed ID: 18395194 [TBL] [Abstract][Full Text] [Related]
37. Alzheimer's disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain. Xiong Z; Thangavel R; Kempuraj D; Yang E; Zaheer S; Zaheer A J Alzheimers Dis; 2014; 40(2):297-308. PubMed ID: 24413615 [TBL] [Abstract][Full Text] [Related]
38. BDNF-modified human umbilical cord mesenchymal stem cells-derived dopaminergic-like neurons improve rotation behavior of Parkinson's disease rats through neuroprotection and anti-neuroinflammation. Jiang Z; Wang J; Sun G; Feng M Mol Cell Neurosci; 2022 Dec; 123():103784. PubMed ID: 36228967 [TBL] [Abstract][Full Text] [Related]
39. Interaction between α-synuclein and tau in Parkinson's disease comment on Wills et al.: elevated tauopathy and α-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218. Jellinger KA Exp Neurol; 2011 Jan; 227(1):13-8. PubMed ID: 20965169 [TBL] [Abstract][Full Text] [Related]
40. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Wills J; Jones J; Haggerty T; Duka V; Joyce JN; Sidhu A Exp Neurol; 2010 Sep; 225(1):210-8. PubMed ID: 20599975 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]